Symbols / EXEL Stock $52.70 +0.40% Exelixis, Inc.

Healthcare • Biotechnology • United States • NMS
EXEL (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Michael M. Morrissey Ph.D.
Exch · Country NMS · United States
Market Cap 13.25B
Enterprise Value 12.64B
Income 833.42M
Sales 2.38B
FCF (ttm) 629.12M
Book/sh 7.63
Cash/sh 3.09
Employees 1,077
Insider 10d —
IPO Apr 17, 2000
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 17.45
Forward P/E 13.02
PEG 2.56
P/S 5.58
P/B 6.91
P/C —
EV/EBITDA 12.82
EV/Sales 5.32
Quick Ratio 3.01
Current Ratio 3.26
Debt/Eq 8.76
LT Debt/Eq —
EPS (ttm) 3.02
EPS next Y 4.05
EPS Growth 43.60%
Revenue Growth 10.00%
EPS Gr Q/Q 31.90%
Rev Gr Q/Q —
Earnings (next) 2026-08-04
Earnings (prior) 2026-05-05
ROA 22.03%
ROE 40.99%
ROIC —
Gross Margin 96.44%
Oper. Margin 41.15%
Profit Margin 35.08%
Shs Outstand 251.36M
Shs Float 204.48M
Insider Own 1.82%
Instit Own 107.53%
Short Float 16.38%
Short Ratio 10.60
Short Interest 30.28M
52W High 52.98
vs 52W High -0.53%
52W Low 33.76
vs 52W Low 56.10%
Beta 0.43
Impl. Vol. 68.38%
Rel Volume 0.79
Avg Volume 2.65M
Volume 2.10M
Target (mean) $49.65
Tgt Median $50.00
Tgt Low $40.00
Tgt High $62.00
# Analysts 17
Recom Buy
Prev Close $52.49
Price $52.70
Change 0.40%
About

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent oral inhibitor of kinases, including the TAM kinases, MET, and VEGF receptors; XL309, a small molecule inhibitor of USP1, a synthetic lethal target in the context of BRCA-mutated tumors; XB010, an antibody-drug conjugates (ADC) consisting of a MMAE payload conjugated to a monoclonal antibody targeting the tumor antigen 5T4; XB628, a first-in-class bispecific antibody that targets programmed cell death ligand 1and natural killer cell receptor group 2A; and XB371, a next-generation tissue factor targeting ADC with a topoisomerase inhibitor payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Catalent, Inc.; Iconic Therapeutics, Inc.; Adagene Inc.; Invenra, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as business development activities and other collaborations. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$49.65
Mean price target
2. Current target
$52.70
Latest analyst target
3. DCF / Fair value
$45.05
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$52.70
Low
$40.00
High
$62.00
Mean
$49.65

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-07 main HC Wainwright & Co. Buy → Buy $56
2026-05-06 main TD Cowen Buy → Buy $55
2026-05-06 main Morgan Stanley Equal-Weight → Equal-Weight $50
2026-05-06 main Stifel Hold → Hold $47
2026-05-06 main Wells Fargo Equal-Weight → Equal-Weight $40
2026-04-20 main Barclays Equal-Weight → Equal-Weight $45
2026-03-02 main RBC Capital Sector Perform → Sector Perform $43
2026-02-12 main HC Wainwright & Co. Buy → Buy $54
2026-02-11 main RBC Capital Sector Perform → Sector Perform $46
2026-02-11 main Stifel Hold → Hold $44
2026-02-11 main Wells Fargo Equal-Weight → Equal-Weight $35
2026-02-04 main Barclays Equal-Weight → Equal-Weight $44
2026-02-03 reit HC Wainwright & Co. Buy → Buy $52
2026-02-02 main Morgan Stanley Equal-Weight → Equal-Weight $49
2026-01-27 main HC Wainwright & Co. Buy → Buy $52
2026-01-08 main HC Wainwright & Co. Buy → Buy $52
2026-01-08 down Morgan Stanley Overweight → Equal-Weight $48
2025-11-06 main UBS Neutral → Neutral $40
2025-11-05 main TD Cowen Buy → Buy $51
2025-11-05 main Morgan Stanley Overweight → Overweight $45
News
RSS: Latest EXEL news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-06-01 WYSZOMIERSKI JACK L Director — 3,925 $50.55 $198,409
2026-06-01 ECKHARDT SUE GAIL Director — 9,812 $50.14 $491,974
2026-05-27 HEYMAN TOMAS J. Director — 8,367 $0.00 $0
2026-05-27 ECKHARDT SUE GAIL Director — 8,367 $0.00 $0
2026-05-27 OLIVER ROBERT LEE JR. Director — 8,367 $0.00 $0
2026-05-27 WYSZOMIERSKI JACK L Director — 8,367 $0.00 $0
2026-05-27 PAPADOPOULOS STELIOS B Director — 8,367 $0.00 $0
2026-05-27 POSTE GEORGE H Director — 8,367 $0.00 $0
2026-05-27 BECKERLE MARY C Director — 8,367 $0.00 $0
2026-05-27 FREIRE MARIA C Director — 8,367 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
2,320.13
+6.98%
2,168.70
+18.49%
1,830.21
+13.60%
1,611.06
Operating Revenue
3,209.13
+11.52%
2,877.55
+16.32%
2,473.86
+14.48%
2,160.99
Cost Of Revenue
83.70
+9.82%
76.22
+5.06%
72.55
+25.28%
57.91
Reconciled Cost Of Revenue
83.70
+9.82%
76.22
+5.06%
72.55
+25.28%
57.91
Gross Profit
2,236.43
+6.88%
2,092.49
+19.05%
1,757.66
+13.17%
1,553.15
Operating Expense
1,343.73
-4.19%
1,402.54
-11.61%
1,586.78
+17.39%
1,351.67
Research And Development
825.00
-9.38%
910.41
-12.80%
1,044.07
+17.07%
891.81
Selling General And Administration
518.73
+5.40%
492.13
-9.32%
542.71
+18.02%
459.86
General And Administrative Expense
518.73
+5.40%
492.13
-9.32%
542.71
—
Salaries And Wages
72.19
+14.29%
63.17
-12.30%
72.03
—
Other Gand A
446.54
+4.10%
428.96
-8.86%
470.68
—
Total Expenses
1,427.42
-3.47%
1,478.75
-10.88%
1,659.32
+17.72%
1,409.58
Operating Income
892.70
+29.39%
689.95
+303.75%
170.88
-15.19%
201.48
Total Operating Income As Reported
872.19
+44.26%
604.62
+253.82%
170.88
-15.19%
201.48
EBITDA
921.76
+28.24%
718.75
+265.59%
196.60
-11.58%
222.36
Normalized EBITDA
942.27
+17.19%
804.08
+308.99%
196.60
-11.58%
222.36
Reconciled Depreciation
29.05
+0.87%
28.80
+12.00%
25.72
+23.20%
20.88
EBIT
892.70
+29.39%
689.95
+303.75%
170.88
-15.19%
201.48
Total Unusual Items
-20.51
+75.96%
-85.33
0.00
0.00
Total Unusual Items Excluding Goodwill
-20.51
+75.96%
-85.33
0.00
0.00
Special Income Charges
-20.51
+75.96%
-85.33
0.00
0.00
Impairment Of Capital Assets
0.00
-100.00%
64.39
0.00
0.00
Restructuring And Mergern Acquisition
20.51
-2.06%
20.94
0.00
0.00
Net Income
782.57
+50.13%
521.27
+150.89%
207.76
+13.98%
182.28
Pretax Income
941.21
+38.08%
681.64
+164.69%
257.52
+9.89%
234.35
Net Non Operating Interest Income Expense
69.21
-10.29%
77.16
-10.85%
86.54
+161.74%
33.06
Net Interest Income
69.21
-10.29%
77.16
-10.85%
86.54
+161.74%
33.06
Interest Income Non Operating
69.21
-10.29%
77.16
-10.85%
86.54
+161.74%
33.06
Interest Income
69.21
-10.29%
77.16
-10.85%
86.54
+161.74%
33.06
Other Income Expense
-20.71
+75.77%
-85.47
-91997.85%
0.09
+147.21%
-0.20
Other Non Operating Income Expenses
-0.20
-48.87%
-0.13
-243.01%
0.09
+147.21%
-0.20
Tax Provision
158.64
-1.08%
160.37
+222.32%
49.76
-4.44%
52.07
Tax Rate For Calcs
0.00
-28.09%
0.00
+21.76%
0.00
-13.14%
0.00
Tax Effect Of Unusual Items
-3.47
+82.71%
-20.05
0.00
0.00
Net Income Including Noncontrolling Interests
782.57
+50.13%
521.27
+150.89%
207.76
+13.98%
182.28
Net Income From Continuing Operation Net Minority Interest
782.57
+50.13%
521.27
+150.89%
207.76
+13.98%
182.28
Net Income From Continuing And Discontinued Operation
782.57
+50.13%
521.27
+150.89%
207.76
+13.98%
182.28
Net Income Continuous Operations
782.57
+50.13%
521.27
+150.89%
207.76
+13.98%
182.28
Normalized Income
799.61
+36.33%
586.55
+182.31%
207.76
+13.98%
182.28
Net Income Common Stockholders
782.57
+50.13%
521.27
+150.89%
207.76
+13.98%
182.28
Diluted EPS
2.78
+57.95%
1.76
+170.77%
0.65
+16.07%
0.56
Basic EPS
2.88
+60.00%
1.80
+176.92%
0.65
+16.07%
0.56
Basic Average Shares
271.57
-6.37%
290.03
-8.84%
318.15
-1.97%
324.56
Diluted Average Shares
281.86
-4.82%
296.13
-7.88%
321.46
-0.95%
324.56
Diluted NI Availto Com Stockholders
782.57
+50.13%
521.27
+150.89%
207.76
+13.98%
182.28
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
2,844.42
-3.50%
2,947.69
+0.18%
2,942.36
-4.20%
3,071.49
Current Assets
1,443.29
-1.66%
1,467.58
+11.35%
1,317.96
-18.58%
1,618.76
Cash Cash Equivalents And Short Term Investments
1,059.09
-4.70%
1,111.28
+11.65%
995.30
-23.93%
1,308.47
Cash And Cash Equivalents
482.49
+121.96%
217.37
-17.35%
262.99
-47.53%
501.19
Other Short Term Investments
576.60
-35.50%
893.90
+22.07%
732.31
-9.29%
807.27
Receivables
286.92
+8.09%
265.44
+11.81%
237.41
+10.53%
214.78
Accounts Receivable
286.92
+8.09%
265.44
+11.81%
237.41
+10.53%
214.78
Inventory
21.69
-3.14%
22.39
+29.24%
17.32
-47.98%
33.30
Prepaid Assets
—
—
—
—
Other Current Assets
75.60
+10.39%
68.48
+0.81%
67.93
+9.19%
62.21
Total Non Current Assets
1,401.13
-5.34%
1,480.11
-8.88%
1,624.40
+11.82%
1,452.73
Net PPE
441.26
+22.88%
359.11
-23.73%
470.85
+17.36%
401.20
Gross PPE
573.49
+24.72%
459.84
-16.58%
551.24
+19.30%
462.07
Accumulated Depreciation
-132.23
-31.27%
-100.73
-25.30%
-80.39
-32.06%
-60.87
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
40.81
+5.90%
38.54
-13.82%
44.71
+2.50%
43.62
Construction In Progress
3.00
+4.45%
2.88
-88.25%
24.46
+395.95%
4.93
Other Properties
418.60
+34.96%
310.15
-21.09%
393.03
+19.03%
330.18
Leases
111.09
+2.60%
108.28
+21.61%
89.04
+6.84%
83.33
Goodwill And Other Intangible Assets
63.68
+0.00%
63.68
+0.00%
63.68
+0.00%
63.68
Goodwill
63.68
+0.00%
63.68
+0.00%
63.68
+0.00%
63.68
Investments And Advances
603.60
-5.29%
637.29
-12.55%
728.72
-3.70%
756.73
Non Current Deferred Assets
292.58
-30.34%
420.03
+16.30%
361.14
+56.27%
231.11
Non Current Deferred Taxes Assets
292.58
-30.34%
420.03
+16.30%
361.14
+56.27%
231.11
Other Non Current Assets
—
—
—
—
Total Liabilities Net Minority Interest
683.10
-2.90%
703.49
+3.69%
678.45
+16.36%
583.06
Current Liabilities
405.64
+0.46%
403.77
+2.41%
394.28
+21.56%
324.36
Payables And Accrued Expenses
118.15
-13.48%
136.55
+2.73%
132.92
+12.71%
117.93
Payables
29.62
-22.43%
38.19
+13.10%
33.77
+3.37%
32.67
Accounts Payable
29.62
-22.43%
38.19
+13.10%
33.77
+3.37%
32.67
Current Accrued Expenses
88.53
-10.00%
98.36
-0.79%
99.15
+16.29%
85.26
Pensionand Other Post Retirement Benefit Plans Current
102.22
-6.93%
109.83
+17.69%
93.33
+20.95%
77.16
Other Current Liabilities
125.38
+31.96%
95.01
-12.36%
108.42
+37.37%
78.92
Total Non Current Liabilities Net Minority Interest
277.46
-7.43%
299.72
+5.47%
284.17
+9.84%
258.70
Long Term Debt And Capital Lease Obligation
173.04
-9.32%
190.82
+0.46%
189.94
-0.12%
190.17
Long Term Capital Lease Obligation
173.04
-9.32%
190.82
+0.46%
189.94
-0.12%
190.17
Non Current Deferred Liabilities
—
—
—
6.58
Non Current Deferred Revenue
—
—
—
6.58
Other Non Current Liabilities
104.42
-4.11%
108.89
+15.57%
94.22
+37.49%
68.53
Stockholders Equity
2,161.32
-3.69%
2,244.20
-0.87%
2,263.91
-9.02%
2,488.43
Common Stock Equity
2,161.32
-3.69%
2,244.20
-0.87%
2,263.91
-9.02%
2,488.43
Capital Stock
0.26
-7.09%
0.28
-6.93%
0.30
-6.48%
0.32
Common Stock
0.26
-7.09%
0.28
-6.93%
0.30
-6.48%
0.32
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
262.48
-6.83%
281.73
-6.96%
302.79
-6.53%
323.95
Ordinary Shares Number
262.48
-6.83%
281.73
-6.96%
302.79
-6.53%
323.95
Additional Paid In Capital
2,234.41
-4.67%
2,343.91
-3.97%
2,440.71
-3.79%
2,536.85
Retained Earnings
-76.83
+22.12%
-98.65
+43.09%
-173.35
-406.50%
-34.23
Gains Losses Not Affecting Retained Earnings
3.48
+358.05%
-1.35
+64.08%
-3.75
+74.18%
-14.52
Other Equity Adjustments
3.48
+358.05%
-1.35
+64.08%
-3.75
+74.18%
-14.52
Total Equity Gross Minority Interest
2,161.32
-3.69%
2,244.20
-0.87%
2,263.91
-9.02%
2,488.43
Total Capitalization
2,161.32
-3.69%
2,244.20
-0.87%
2,263.91
-9.02%
2,488.43
Working Capital
1,037.64
-2.46%
1,063.81
+15.17%
923.68
-28.64%
1,294.40
Invested Capital
2,161.32
-3.69%
2,244.20
-0.87%
2,263.91
-9.02%
2,488.43
Total Debt
173.04
-9.32%
190.82
+0.46%
189.94
-0.12%
190.17
Capital Lease Obligations
173.04
-9.32%
190.82
+0.46%
189.94
-0.12%
190.17
Net Tangible Assets
2,097.64
-3.80%
2,180.52
-0.90%
2,200.23
-9.26%
2,424.74
Tangible Book Value
2,097.64
-3.80%
2,180.52
-0.90%
2,200.23
-9.26%
2,424.74
Current Provisions
59.90
-3.98%
62.38
+4.62%
59.62
+18.41%
50.35
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
884.27
+26.33%
699.97
+110.00%
333.32
-8.08%
362.61
Cash Flow From Continuing Operating Activities
884.27
+26.33%
699.97
+110.00%
333.32
-8.08%
362.61
Net Income From Continuing Operations
782.57
+50.13%
521.27
+150.89%
207.76
+13.98%
182.28
Depreciation Amortization Depletion
29.05
+0.87%
28.80
+12.00%
25.72
+23.20%
20.88
Depreciation
—
—
25.72
+23.20%
20.88
Depreciation And Amortization
29.05
+0.87%
28.80
+12.00%
25.72
+23.20%
20.88
Other Non Cash Items
24.62
-61.88%
64.58
-54.09%
140.68
+12.51%
125.04
Stock Based Compensation
112.98
+20.40%
93.84
-11.76%
106.34
-1.14%
107.57
Asset Impairment Charge
0.00
-100.00%
64.39
0.00
0.00
Deferred Tax
126.24
+312.31%
-59.46
+55.36%
-133.21
-120.70%
-60.36
Deferred Income Tax
126.24
+312.31%
-59.46
+55.36%
-133.21
-120.70%
-60.36
Change In Working Capital
-191.20
-1321.22%
-13.45
+3.72%
-13.97
-9.17%
-12.80
Change In Receivables
-21.40
+23.44%
-27.95
-23.55%
-22.62
-133.84%
66.85
Changes In Account Receivables
-21.40
+23.44%
-27.95
-23.55%
-22.62
-133.84%
66.85
Change In Inventory
12.22
+124.19%
5.45
+142.02%
-12.98
-11.08%
-11.68
Change In Prepaid Assets
-133.77
-530.42%
31.08
+204.21%
-29.82
-5.54%
-28.26
Change In Payables And Accrued Expense
-48.25
-118.98%
-22.04
-142.83%
51.45
+229.58%
-39.71
Change In Accrued Expense
1.90
+1374.50%
-0.15
-111.08%
1.34
+102.13%
-63.06
Change In Payable
-50.15
-129.15%
-21.89
-143.68%
50.11
+114.50%
23.36
Change In Account Payable
-50.15
-129.15%
-21.89
-143.68%
50.11
+114.50%
23.36
Change In Other Working Capital
—
—
-3.14
-26.46%
-2.48
Investing Cash Flow
350.44
+400.08%
-116.78
-333.25%
-26.95
+94.86%
-524.41
Cash Flow From Continuing Investing Activities
350.44
+400.08%
-116.78
-333.25%
-26.95
+94.86%
-524.41
Net PPE Purchase And Sale
-8.43
+70.36%
-28.43
+29.74%
-40.47
-46.07%
-27.71
Purchase Of PPE
-8.43
+70.36%
-28.43
+29.74%
-40.47
-46.07%
-27.71
Capital Expenditure
-39.93
+39.67%
-66.19
+59.39%
-162.97
-17.70%
-138.46
Net Investment Purchase And Sale
390.37
+871.51%
-50.60
-137.20%
136.01
+135.24%
-385.96
Purchase Of Investment
-632.50
+31.84%
-927.90
-2.82%
-902.47
+37.79%
-1,450.72
Sale Of Investment
1,022.87
+16.59%
877.31
-15.52%
1,038.48
-2.47%
1,064.76
Net Intangibles Purchase And Sale
-31.50
+16.56%
-37.75
+69.18%
-122.50
-10.61%
-110.75
Purchase Of Intangibles
-31.50
+16.56%
-37.75
+69.18%
-122.50
-10.61%
-110.75
Financing Cash Flow
-969.59
-54.20%
-628.81
-15.16%
-546.05
-93282.94%
0.59
Cash Flow From Continuing Financing Activities
-969.59
-54.20%
-628.81
-15.16%
-546.05
-93282.94%
0.59
Net Common Stock Issuance
-947.51
-45.32%
-652.03
-18.47%
-550.38
0.00
Common Stock Payments
-947.51
-45.32%
-652.03
-18.47%
-550.38
0.00
Repurchase Of Capital Stock
-947.51
-45.32%
-652.03
-18.47%
-550.38
0.00
Proceeds From Stock Option Exercised
49.14
-20.55%
61.85
+84.91%
33.45
+40.03%
23.89
Net Other Financing Charges
-71.22
-84.39%
-38.62
-32.63%
-29.12
-24.99%
-23.30
Changes In Cash
265.11
+681.14%
-45.62
+80.97%
-239.68
-48.67%
-161.21
Beginning Cash Position
217.37
-17.35%
262.99
-47.68%
502.68
-24.28%
663.89
End Cash Position
482.49
+121.96%
217.37
-17.35%
262.99
-47.68%
502.68
Free Cash Flow
844.34
+33.22%
633.79
+272.04%
170.35
-24.00%
224.16
Income Tax Paid Supplemental Data
155.30
-8.91%
170.48
-8.17%
185.66
+45.19%
127.87
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category